C-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-methylamine | 282520-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: C-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-methylamine
• 英文别名: 4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl-methylamine；dihydro-4-methyl-2H-1,4-benzoxazine-2-methanamine；(4-Methyl-3,4-dihydro-2H-1,4-benzoxazin-2-YL)methylamine；(4-methyl-2,3-dihydro-1,4-benzoxazin-2-yl)methanamine
• CAS: 282520-55-2
• 化学式: C₁₀H₁₄N₂O
• mdl: MFCD11841068
• 分子量: 178.234
• InChiKey: VPYSMSLDVAQICD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  C-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl)-methylamine 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 [3-(1H-Indol-3-yl)-propyl]-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-2-yl-methyl)-amine
  参考文献：
  名称：

  Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity

  摘要：

  The design, synthesis, and structure-activity relationship of two novel classes of benzoxazine derivatives with dual selective serotonin reuptake inhibitors and 5-HT1A receptor activities are described. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.054

文献信息

• 3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3yl)-alkyl]- amines
  申请人：American Home Products Corp

  公开号：US06313114B1

  公开（公告）日：2001-11-06

  Compounds are provided which have the following formula: wherein: R is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, or substituted phenyl; X and Y are each, independently, hydrogen, halogen, cyano, or alkoxy of 1 to 6 carbon atoms; and m is 1 to 5; or a pharmaceutically acceptable salt thereof.

  提供具有以下化学式的化合物：其中：R为氢、1至6个碳原子的烷基、苯基或取代苯基；X和Y分别独立地为氢、卤素、氰基或1至6个碳原子的烷氧基；m为1至5；或其药用可接受盐。
• 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：Lim Sungtaek

  公开号：US20070244131A1

  公开（公告）日：2007-10-18

  The present invention is directed to a compound of Formula (I) wherein Cy 1 , Cy 2 , L 1 , L 2 , and R 1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

  本发明涉及一种式（I）的化合物，其中Cy1，Cy2，L1，L2和R1如本文所定义，一种制药组合物，包括一种或多种按照式（I）的化合物的药物有效量与药学可接受载体的混合物，以及一种治疗患有PGD2介导的疾病的患者的方法，包括但不限于过敏性疾病（如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），全身性肥大细胞病，伴随全身性肥大细胞激活的疾病，过敏性休克，支气管收缩，支气管炎，荨麻疹，湿疹，伴随瘙痒的疾病（如特应性皮炎和荨麻疹），疾病（如白内障，视网膜脱落，炎症，感染和睡眠障碍），这些疾病是由于伴随瘙痒的行为（如搔抓和敲打）而次生产生的，炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等，通过向该患者注射按照式（I）的化合物的药物有效量。
• 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists
  申请人：Aventis Pharmaceuticals, Inc.

  公开号：US07517889B2

  公开（公告）日：2009-04-14

  The present invention is directed to a compound of Formula (I) wherein Cy1, Cy2, L1, L2, and R1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

  本发明涉及一种式(I)化合物，其中Cy1、Cy2、L1、L2和R1的定义如本文所述，一种制药组合物，包括一种或多种式(I)化合物的药物有效量与药物可接受载体混合，以及一种治疗患有PGD2介导的疾病的患者的方法，包括但不限于过敏疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身肥大细胞病、伴随全身肥大细胞激活的疾病、过敏性休克、支气管收缩、支气管炎、荨麻疹、湿疹、伴随瘙痒的疾病（如特应性皮炎和荨麻疹）、由于瘙痒行为（如搔抓和打击）引起的疾病（如白内障、视网膜脱落、炎症、感染和睡眠障碍）、炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、慢性类风湿性关节炎、胸膜炎、溃疡性结肠炎等，通过向该患者投予符合式(I)的化合物的药物有效量实施。
• NOVEL DERIVATIVES OF ARYL--METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
  申请人：Vacher Bernard

  公开号：US20120115860A1

  公开（公告）日：2012-05-10

  The present invention concerns compounds of general formula (1) (I) wherein R 1 is: a hydrogen atom, or a halogen, a straight or branched C 1 -C 6 alkyl group or a C 1 -C 3 fluoroalkyl group, a straight or branched C 1 -C 6 alcoxy group, a carbamyl group, N-substituted or not by one or two, straight or branched C 1 -C 3 alkyl groups, or a cyano group (CN) R2 is: a hydrogen atom or a straight or branched C 1 -C 6 alkyl group, HaI 1 , Hal 2 and Hal 3 are: a halogen their addition salts and the hydrates of addition salts with pharmaceutically acceptable mineral acids or organic acids, and their enantiomer forms.

  本发明涉及一般式（1）（I）的化合物，其中R1为：氢原子，或卤素，直链或支链C1-C6烷基或C1-C3氟烷基，直链或支链C1-C6烷氧基，氨基甲酰基，由一或两个直链或支链C1-C3烷基取代或未取代的N-取代基，或氰基（CN）。R2为：氢原子或直链或支链C1-C6烷基，HaI1，Hal2和Hal3为：卤素，它们的加成盐和与药学上可接受的无机酸或有机酸的加成盐的水合物，以及它们的对映异构体形式。
• WO2006/44732
  申请人：——

  公开号：——

  公开（公告）日：——